Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis

Expert Opinion on Biological Therapy

Volumn 13, Issue 11, 2013, Pages 1623-1630

  Berard, Roberta A ^a   Laxer, Ronald M ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Clinical efficacy; Drug evaluation; Etanercept; Juvenile idiopathic arthritis; Tumor necrosis factor inhibition

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

AORTA ARCH SYNDROME; ARTICLE; BIOLOGICAL THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; COST BENEFIT ANALYSIS; CROHN DISEASE; DEMYELINATION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HODGKIN DISEASE; HUMAN; INFECTION; JOINT INJURY; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE COUNT; MACROPHAGE ACTIVATION SYNDROME; MENORRHAGIA; MORBIDITY; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; REMISSION; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; UTERINE CERVIX DYSPLASIA; UVEITIS; VASCULITIS; YOLK SAC TUMOR;

ADOLESCENT; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN G; INFANT; MEDICATION ADHERENCE; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PATIENT PREFERENCE; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; REMISSION INDUCTION; SAMPLE SIZE; SELECTION BIAS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885627207     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.840580     Document Type: Article

References (69)

1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004á31(2):390-2
2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007á369:767-78
3. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Education and employment. Rheumatology (Oxford) 2002á41(12):1436-9
4. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Functional outcome. Rheumatology (Oxford) 2002á41(12):1428-35
5. Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Predictive factors for mood and pain. Rheumatology (Oxford) 2002á41(12):1444-9
6. Foster HE, Marshall N, Myers A, et al. Outcome in adults with juvenile idiopathic arthritis: A quality of life study. Arthritis Rheum 2003á48(3):767-75
7. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Social function, relationships and sexual activity. Rheumatology (Oxford) 2002á41(12):1440-3
8. Minden K, Niewerth M, Listing J, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002á46(9):2392-401
9. Beukelman T, Patkar NM, Saag KG, et al. 2011á American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011á63(4):465-82
10. Gattorno M, Picco P, Buoncompagni A, et al. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis 1996á55(4):243-7
11. Gattorno M, Picco P, Buoncompagni A, et al. Tumor necrosis factor receptor p75 correlates better than p55 with disease activity in juvenile rheumatoid arthritis: Comment on the article by Mangge et al. Arthritis Rheum 1996á39(5):883-4
12. Mangge H, Gallistl S, Schauenstein K. Long-term follow-up of cytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis. J Interferon Cytokine Res 1999á19(9):1005-10
13. Enbrel (package insert). Immunex Corp., Thousand Oaks (CA)á 1998 2009
14. Yim DS, Zhou H, Buckwalter M, et al. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2005á45(3):246-56
15. Prince FH, Twilt M, Jansen-Wijngaarden NC, van Suijlekom-Smit LW. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: A clinical study. Ann Rheum Dis 2007á66(5):704-5
16. Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford, England) 2009á48(8):916-19
17. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children wiht polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000á342:763-9
18. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997á40(7):1202-9
19. Brewer EJ, Bass J, Baum J, et al. Current proposed revision of JRA criteria. Arthritis Rheum 1977á20(Suppl 2):195-9
20. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004á31(11):2290-4
21. Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006á54(6):1987-94
22. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008á58(5):1496-504
23. Ungar WJ, Costa V, Burnett HF, et al. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: A systematic review. Semin Arthritis Rheum 2013á42(6):597-618
24. Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: Part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2013 [Epub ahead of print]
25. Russo RA, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 2002á20(5):723-6
26. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005á32(5):935-42
27. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003á48(4):1093-101
28. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: The Dutch national register. Ann Rheum Dis 2009á68(5):635-41
29. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005á52(7):2103-8
30. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004á31(10):2055-61
31. Otten MH, Prince FH, Twilt M, et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis-data from the dutch arthritis and biologicals in children register, 1999 - 2010. J Rheumatol 2011á38(10):2258-63
32. Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine 2009á76(1):24-7
33. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006á45(8):982-9
34. Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007á66(4):548-50
35. Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J Aapos 2008á12(6):611-13
36. Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013á40(1):74-9
37. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006á149(4):572-5
38. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004á63(12):1638-44
39. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): Preliminary data from the German JIA Registry. Ann Rheum Dis 2009á68(4):519-25
40. Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford, England) 2011á50(1):189-95
41. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: Forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010 62(8):2517-24
42. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012á64(4):1263-71
43. Bernatsky S, Rosenberg AM, Oen KG, et al. Malignancies in juvenile idiopathic arthritis: A preliminary report. J Rheumatol 2011á38(4):760-3
44. Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: A nationwide cohort study. Arthritis Rheum 2010 62(12):3776-82
45. Beukelman T, Xie F, Chen L, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012á64(8):2773-80
46. Beukelman T, Xie F, Baddley JW, et al. Brief report: Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum 2013á65(5):1384-9
47. Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 2010 6(10):561-71
48. Halbig M, Horneff G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 2009á30(2):229-38
49. Prince FH, Geerdink LM, Borsboom GJ, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis 2010 69(1):138-42
50. Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008á26(4):688-92
51. Simonini G, Giani T, Stagi S, et al. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford, England) 2005á44(6):777-80
52. Billiau AD, Loop M, Le PQ, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford, England) 2010 49(8):1550-8
53. Vojvodich PF, Hansen JB, Andersson U, et al. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol 2007á34(12):2481-5
54. Prince FH, de Bekker-Grob EW, Twilt M, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: Results from the Dutch Arthritis and Biologicals in Children register. Rheumatology (Oxford, England) 2011á50(6):1131-6
55. Burnett HF, Regier DA, Feldman BM, et al. Parents' preferences for drug treatments in juvenile idiopathic arthritis: A discrete choice experiment. Arthritis Care Res (Hoboken) 2012á64(9):1382-91
56. Ringold S, Grant S, Girdish C, et al. Injectable tumor necrosis alpha factor inhibitors and outpatient antimicrobial use in children with rheumatic diseases: Analyses of prescription claims from a pharmacy benefit manager. Arthritis Care Res (Hoboken) 2013 [Epub ahead of print]
57. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003á48(7):1771-4
58. Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012á64(6):2012-21
59. Anink J, Otten MH, Gorter SL, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: Etanercept or adalimumab? Rheumatology (Oxford) 2013á52(9):1674-9
60. Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011á306(21):2340-7
61. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line diseasemodifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series. Arthritis Rheum 2011á63(2):545-55
62. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012á367(25):2385-95
63. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012á367(25):2396-406
64. Prince FH, Twilt M, Simon SC, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2009á68(7):1228-9
65. Martini A, Lovell DJ. Juvenile idiopathic arthritis: State of the art and future perspectives. Ann Rheum Dis 2010 69(7):1260-3
66. Hunter PJ, Wedderburn LR. Pediatric rheumatic disease: Can molecular profiling predict the future in JIA? Nat Rev Rheumatol 2009á5(11):593-4
67. Ruperto N, Giannini EH, Pistorio A, et al. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs. Arthritis Rheum 2010 62(11):3131-9
68. Abrahamyan L, Beyene J, Feng J, et al. Response times follow lognormal or gamma distribution in arthritis patients. J Clin Epidemiol 2010 63(12):1363-9
69. Leblanc CM, Lang B, Bencivenga A, et al. Access to biologic therapies in Canada for children with juvenile idiopathic arthritis. J Rheumatol 2012á39(9):1875-9